In the GESTALT feasibility and safety trial, GammaTile reduced rapid early progression to 6% vs a historical 50% to 80%, with 93% of patients starting chemoradiation on schedule.
Clark Chen, MD, PhD
Advertisement
Clark Chen, MD, PhD, is director of the Brain Tumor Program and co-director of the Gamma Knife Stereotactic Radiosurgery Program at Brown University Health.
Articles by Clark Chen, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer
2
ASCO Publishes First Living Guideline for Systemic Treatment of Recurrent Ovarian Cancer
3
Fixed-Duration Mosun-Pola Yields High ORR in R/R Mantle Cell Lymphoma
4
Scaling Agentic AI in Oncology: Implementation, Trust, and Value
5